| EPB0224 | Association of oral lead-in and persistence on cabotegravir and rilpivirine long-acting in ‘real-life’ | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0225 | A Site-driven CQI intervention improves advanced HIV disease screening coverage among newly diagnosed people living with HIV in Malawi | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0226 | Changes in weight and body mass index associated with dolutegravir- and non-dolutegravir-based antiretroviral treatment regimens: a longitudinal analysis | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0227 | Factors associated with viral rebound among PLHIV who achieved viral suppression in Eswatini: a retrospective cohort study | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0228 | Towards colorimetric readout of a rapid enzymatic assay for measuring nucleotide analogs used in ART and PrEP | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0229 | High treatment continuity established among people with HIV devolved to Community Pharmacy Antiretroviral Refill Program (CPARP) in Southern Nigeria | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0230 | Comparison of long-acting lenacapavir Phase 2/3 regimen vs simplified regimen using population-PK analysis and simulation | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0231 | Incidence and types of Adverse Drug Reactions to first-line antiretroviral therapy in Nigeria | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0232 | Prevalence and predictors of persistent low-level HIV viraemia among people receiving Dolutegravir-based antiretroviral therapy in Southern Nigeria | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0233 | Therapeutic monitoring of long-acting injectable rilpivirine using a rapid enzymatic assay | E-poster | Antiretroviral therapies and clinical issues in adults |